FDA Approves Neurocrine Biosciences' Parkinson's Drug
Neurocrine Biosciences (NASDAQ: NBIX) announced Monday that the Food and Drug Administration (FDA) has approved Ongentys (opicapone), a daily pill for Parkinson's disease.
Ongentys is an add-on treatment for Parkinson's patients who are currently taking the main first-line treatment, levodopa (L-Dopa), combined with carbidopa to moderate side effects. As the disease progresses, some patients experience more frequent episodes of motor-function issues between their levodopa treatments. Ongentys is a COMT inhibitor, a drug that blocks the enzyme that breaks down levodopa, therefore prolonging its clinical effects during those "off times."
Image source: Getty Images.
Source Fool.com
